Literature DB >> 24606577

Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study.

Hirozumi Sano1, Ryoji Kobayashi, Junji Tanaka, Satoshi Hashino, Shuichi Ota, Yoshihiro Torimoto, Yasutaka Kakinoki, Satoshi Yamamoto, Mitsutoshi Kurosawa, Naoki Hatakeyama, Yoshihito Haseyama, Hajime Sakai, Kazuya Sato, Takashi Fukuhara.   

Abstract

Haemophagocytic syndrome is often associated with malignant lymphoma; however, few studies have examined lymphoma-associated haemophagocytic syndrome (LAHS). A total of 1239 patients with non-Hodgkin lymphoma were analysed at 12 institutions in Hokkaido prefecture between January 2007 and December 2011 to assess the incidence, prognosis and risk factors of LAHS. The cumulative incidence rate of LAHS was 2·8% (35/1239). Overall survival (OS) in patients with LAHS was significantly inferior to those without LAHS (3-year OS: 35·6 vs. 59·0% respectively, P < 0·0001). The cumulative incidence of LAHS was higher in patients with T/Natural Killer (NK)-cell lymphoma than in those with B-cell lymphoma (8·2 vs. 1·8% respectively, P < 0·0001). The characteristics of patients with and without early death (within the first 120 d after developing LAHS) were subsequently compared to evaluate the prognostic factor of LAHS. The results obtained showed that the rate of early death after developing LAHS was higher in patients with T/NK-cell lymphoma than in those with B-cell lymphoma (62·5 vs. 10·5%, P = 0·0033). In conclusion, the complication and mortality rates of LAHS were higher in patients with T/NK-cell lymphoma after they developed LAHS than in those with B-cell lymphoma.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell lymphoma; T/NK cell lymphoma; lymphoma-associated haemophagocytic syndrome; prognostic factor; risk factor

Mesh:

Year:  2014        PMID: 24606577     DOI: 10.1111/bjh.12823

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial.

Authors:  Jin-Hua Liang; Li Wang; Hua-Yuan Zhu; Jun Qian; Hui Liao; Jia-Zhu Wu; Yi Xia; Wei Wu; Lei Cao; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Haematologica       Date:  2019-05-09       Impact factor: 9.941

2.  A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma.

Authors:  Na Li; Li Zhang; Jie Liu; Jing Zhang; Hua-Wei Weng; Hong-Yu Zhuo; Li-Qun Zou
Journal:  Cancer Biol Ther       Date:  2017-02-25       Impact factor: 4.742

3.  Lymphoma associated hemophagocytic syndrome: A single-center retrospective study.

Authors:  Yu Chang; Meng Cui; Xiaorui Fu; Lijuan Han; Lei Zhang; Ling Li; Xin Li; Zhenchang Sun; Jingjing Wu; Xudong Zhang; Zhaoming Li; Feifei Nan; Jiaqin Yan; Guangyao Sheng; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

4.  Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.

Authors:  Haijun Wen; Huajuan Ma; Qichun Cai; Suxia Lin; Xinxing Lei; Bin He; Sijin Wu; Zifeng Wang; Yan Gao; Wensheng Liu; Weiping Liu; Qian Tao; Zijie Long; Min Yan; Dali Li; Keith W Kelley; Yongliang Yang; Huiqiang Huang; Quentin Liu
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

Review 5.  Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy.

Authors:  Eric J Vick; Kruti Patel; Philippe Prouet; Mike G Martin
Journal:  Blood Adv       Date:  2017-05-09

6.  Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.

Authors:  Yubo Pi; Jingshi Wang; Hui Zhou; Xiujin Ye; Xiuhua Sun; Ligen Liu; Xueyi Pan; Zhao Wang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-19       Impact factor: 4.322

7.  An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis.

Authors:  Adi Zoref-Lorenz; Jun Murakami; Liron Hofstetter; Swaminathan Iyer; Ahmad S Alotaibi; Shehab Fareed Mohamed; Peter G Miller; Elad Guber; Shiri Weinstein; Joanne Yacobovich; Sarah Nikiforow; Benjamin L Ebert; Adam Lane; Oren Pasvolsky; Pia Raanani; Arnon Nagler; Nancy Berliner; Naval Daver; Martin Ellis; Michael B Jordan
Journal:  Blood       Date:  2022-02-17       Impact factor: 25.476

8.  Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.

Authors:  Yue Song; Jingshi Wang; Yini Wang; Lin Wu; Zhao Wang
Journal:  Cancer Biol Ther       Date:  2021-11-01       Impact factor: 4.742

9.  Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report.

Authors:  Ran Wu; Xiaohui Deng; Siguo Hao; Liyuan Ma
Journal:  J Int Med Res       Date:  2019-10-23       Impact factor: 1.671

10.  A rare case of diffuse large B cell lymphoma-associated hemophagocytic syndrome initially present in the bone marrow with a favorable clinical course.

Authors:  Sang Hyuk Park; Eun Yup Lee; Joo Seop Chung
Journal:  Blood Res       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.